These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8174251)

  • 1. Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content.
    Nurminen M; Dejmek A; Mårtensson G; Thylen A; Hjerpe A
    Clin Chem; 1994 May; 40(5):777-80. PubMed ID: 8174251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids.
    Hjerpe A
    Clin Chem; 1986 Jun; 32(6):952-6. PubMed ID: 3708819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma.
    Roboz J; Greaves J; Silides D; Chahinian AP; Holland JF
    Cancer Res; 1985 Apr; 45(4):1850-4. PubMed ID: 3978644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum hyaluronate in malignant pleural mesothelioma.
    Frebourg T; Lerebours G; Delpech B; Benhamou D; Bertrand P; Maingonnat C; Boutin C; Nouvet G
    Cancer; 1987 Jun; 59(12):2104-7. PubMed ID: 3567871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.
    Welker L; Müller M; Holz O; Vollmer E; Magnussen H; Jörres RA
    Virchows Arch; 2007 Apr; 450(4):455-61. PubMed ID: 17377812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
    Adell E; Dejmek A
    Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronan in pleural effusions and in serum.
    Hillerdal G; Lindqvist U; Engström-Laurent A
    Cancer; 1991 May; 67(9):2410-4. PubMed ID: 2013045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-erbB-2 oncoprotein immunostaining in serous effusions.
    Ascoli V; Scalzo CC; Nardi F
    Cytopathology; 1993; 4(4):207-18. PubMed ID: 8104524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.
    Atagi S; Ogawara M; Kawahara M; Sakatani M; Furuse K; Ueda E; Yamamoto S
    Jpn J Clin Oncol; 1997 Oct; 27(5):293-7. PubMed ID: 9390204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.
    Martensson G; Thylen A; Lindquist U; Hjerpe A
    Cancer; 1994 Mar; 73(5):1406-10. PubMed ID: 8111707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.
    Pettersson T; Fröseth B; Riska H; Klockars M
    Chest; 1988 Nov; 94(5):1037-9. PubMed ID: 3180855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyaluronic acid in pleural fluids: an additional parameter for clinical diagnosis on diffuse mesotheliomas (author's transl)].
    Matzel W; Schubert G
    Arch Geschwulstforsch; 1979; 49(2):146-54. PubMed ID: 475551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thoracoscopy in the diagnosis of malignant mesothelioma.
    Martensson G
    Poumon Coeur; 1981; 37(4):249-51. PubMed ID: 7312754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-performance capillary electrophoretic analysis of hyaluronan in effusions from human malignant mesothelioma.
    Karamanos NK; Hjerpe A
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 697(1-2):277-81. PubMed ID: 9342681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
    Kobzik L; Antman KH; Warhol MJ
    Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel biotinylated probe specific for hyaluronate. Its diagnostic value in diffuse malignant mesothelioma.
    Azumi N; Underhill CB; Kagan E; Sheibani K
    Am J Surg Pathol; 1992 Feb; 16(2):116-21. PubMed ID: 1733346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.